Statement of Ownership (sc 13g)
February 13 2020 - 04:02PM
Edgar (US Regulatory)
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
Neoleukin
Therapeutics, Inc.
(Name of Issuer)
Common Stock, par value $0.000001 per share
(Title of Class of Securities)
64049K104
(CUSIP Number)
December 31, 2019
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to
designate the rule pursuant to which this Schedule is filed:
☐ Rule 13d-1(b)
☐ Rule 13d-1(c)
☒ Rule 13d-1(d)
The information required on the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities
Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
SCHEDULE 13G
|
|
|
CUSIP No. 64049K104
|
|
Page
2
of 4 Pages
|
|
|
|
|
|
|
|
1
|
|
NAME OF REPORTING PERSON
S.S. OR I.R.S.
IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)
Umut
Ulge
|
2
|
|
CHECK THE APPROPRIATE BOX
IF A MEMBER OF A GROUP (See Instructions)
(a) ☐ (b) ☐
|
3
|
|
SEC USE ONLY
|
4
|
|
CITIZENSHIP OR PLACE OF
ORGANIZATION
United
States
|
|
|
|
|
|
|
|
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
|
|
5
|
|
SOLE VOTING POWER
3,111,896
|
|
6
|
|
SHARED VOTING POWER
0
|
|
7
|
|
SOLE DISPOSITIVE POWER
3,111,896
|
|
8
|
|
SHARED DISPOSITIVE POWER
0
|
|
|
|
|
|
|
|
9
|
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
3,111,896
|
10
|
|
CHECK BOX IF THE AGGREGATE
AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions)
☐
|
11
|
|
PERCENT OF CLASS
REPRESENTED BY AMOUNT IN ROW (9)
8.20%
|
12
|
|
TYPE OF REPORTING PERSON
(See Instructions)
IN
|
SCHEDULE 13G
|
|
|
CUSIP No. 64049K104
|
|
Page
3
of 4 Pages
|
Neoleukin Therapeutics, Inc.
|
(b)
|
Address of Issuers Principal Executive Offices:
|
1616 Eastlake Avenue East, #360
Seattle, Washington 98102
|
(a)
|
Name of Person Filing:
|
Umut Ulge
|
(b)
|
Address of Principal Office:
|
c/o Neoleukin Therapeutics, Inc.
1616 Eastlake Avenue East, #360
Seattle, Washington 98102
United States
|
(d)
|
Title of Class of Securities:
|
Common Stock
64049K104
Item 3.
|
Statement Filed Pursuant to Rule 13d-1(b) or 13d-2(b) or (c):
|
Not applicable.
|
(a)
|
Amount beneficially owned:
|
3,111,896
8.20%
|
(c)
|
Number of shares as to which the person has:
|
|
|
|
|
|
|
|
|
|
|
|
(i)
|
|
Sole power to vote or to direct the vote:
|
|
|
3,111,896
|
|
|
|
|
|
(ii)
|
|
Shared power to vote or to direct the vote:
|
|
|
0
|
|
|
|
|
|
(iii)
|
|
Sole power to dispose or to direct the disposition of:
|
|
|
3,111,896
|
|
|
|
|
|
(iv)
|
|
Shared power to dispose or to direct the disposition of:
|
|
|
0
|
|
|
|
|
|
Item 5.
|
Ownership of Five Percent or Less of a Class.
|
If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of
more than five percent of the class of securities, check the following [ ].
Item 6.
|
Ownership of More Than Five Percent on Behalf of Another Person.
|
Not Applicable.
Item 7.
|
Identification and Classification of Subsidiary Which Acquired the Security Being Reported on by the Parent
Holding Company or Control Person
|
Not applicable.
Item 8.
|
Identification and Classification of Members of the Group
|
Not applicable.
Item 9.
|
Notice of Dissolution of Group
|
Not applicable.
Not applicable.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
|
|
|
|
|
|
|
Dated: February 13, 2020
|
|
|
|
|
|
/s/ Umut Ulge
|
|
|
Name:
|
|
|
|
Umut Ulge
|
Neoleukin Therapeutics (NASDAQ:NLTX)
Historical Stock Chart
From Feb 2024 to Mar 2024
Neoleukin Therapeutics (NASDAQ:NLTX)
Historical Stock Chart
From Mar 2023 to Mar 2024